Previous editions of BioBucks

Pfizer inks a 12-asset oncology pact, SHINE wins Europe for Ilumira, and healthcare finally leads the tape.

$1.3B for Apogee with zero dilution, a hepatitis B functional cure from GSK, and a faster FDA clock for Sanofi.

Lilly buys three vaccine makers for up to $3.8B, EMA's CHMP greenlights four, and Kardigan tests the IPO window.

Lilly posts early Verve data, ASCO names to watch sharpen, and neuromuscular FDA clocks speed up.

Lilly's triple agonist hits Phase 3 in obesity, Biogen and Denali scrap BIIB122, and Retro lands at a $1.8B valuation.

BioMarin lands Phase 3 data, Lilly adds delivery tech, and cAMPfield puts up a $180M Series A.

Paragon's Mentari hits Nasdaq via reverse merger with $290M PIPE, Relay scores in vascular anomalies and tags a $175M raise, and Regeneron seeds a $2.3B Helicon bet at Parabilis.

Hansa’s licensing win, private cash, and a softer biotech tape set the tone.

Candel adds follow-up ahead of filing, Aardvark hits a hold, and FDA leadership churn clouds the setup.

A live tracker of the most active biotech and biopharma investors this year — ranking VCs, crossover funds, hedge funds, asset managers and pharma strategics by qualifying deal participation.

Track 2026 biotech/biopharma licensing + partnering deals — upfronts, milestones, royalties, rights/territory, and a one-line “why it matters.”

Diranersen lives, RGX-202 hits with a safety asterisk, and Alumis tees up a strategic review.

Track April 2026 biotech venture funding: private rounds, deal size, investors, therapeutic area, and quick company summaries.

Fosun pays $60M to option AriBio's AR1001, Ipsen debuts corabotase as first-in-class RNI, and Altimmune queues twin pemvidutide catalysts.

Diamantas takes acting role; BridgeBio bests Pfizer in ATTR-CM; ECO 2026 obesity reads pile up.

BMS drops $600M upfront on Hengrui's pipeline; Roche grabs a pTau217 CE mark; Novo's Wegovy 28% subgroup keeps the obesity arms race live.

Regulatory nerves, a Leqembi delay and one cleaner label win set the pace.

Track March 2026 biotech/biopharma licensing + partnering deals — upfronts, milestones, royalties, rights/territory, and a one-line “why it matters.”

Friday’s prints: LEQEMBI’s PDUFA slip, Odyssey’s $304M IPO/private-placement combo, and Blackstone’s $250M Anagram bet.

Angelini-Catalyst, Roche-PathAI, and Bayer-Perfuse: Big Pharma goes shopping.

Cytokinetics aficamten clears nHCM Phase 3, Avalo pairs Phase 2 HS data with $375M raise, Viridian posts second chronic TED win./

ACACIA-HCM topline today; Vertex ends Moderna-partnered VX-522; BioMarin raises FY26 to ~20% growth.

Axsome expands Auvelity into Alzheimer’s agitation; Veppanu clears FDA; UCB buys Candid for up to $2.2B.

Lilly resets the GLP-1 tape, Hemab and Seaport extend the IPO run, and LEO buys Replay.

Chiesi buys into oral HAE, Teva pays up for Tourette’s, and AZ keeps its EGFR degrader option alive.